Actively Recruiting
Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial
Led by Frieder Schaumburg · Updated on 2024-12-09
100
Participants Needed
1
Research Sites
124 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an exploratory study to evaluate the effect of adjunctive clindamycin in the treatment of skin and soft-tissue infections due to Staphylococcus aureus in patients from Sierra Leone. The study hypothesizes that clindamycin, when added to routine treatment, will lead to a more rapid clinical resolution and less frequent recurrences of infection.
CONDITIONS
Official Title
Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults (age �3e=18 years)
- Require treatment (incision/drainage with or without oral or intravenous antibiotics) for a skin or soft tissue infection
- Infection caused by Staphylococcus aureus confirmed from at least one clinical specimen
- Symptoms started within the last 4 weeks
- Randomisation possible within 72 hours after initial culture collection
- Ability to attend follow-up visits during admission or at home
- Initial culture collected within 48 hours of hospital admission
- Willing to participate in the study
You will not qualify if you...
- Previous allergic reaction to clindamycin
- Prior antibiotic-associated diarrhea
- Previous participation in this study
- Confirmed pregnancy by beta-HCG rapid test
- Started clindamycin treatment before clinic visit
- Systemic antibiotic treatment within the last 14 days
- Use of other protein synthesis inhibitors (e.g., macrolides, rifampicin, linezolid, aminoglycosides, tetracyclines, chloramphenicol)
- Use of toxin inducers such as trimethoprim-sulfamethoxazole
- Severe illness with expected death within 24 hours
- Chronically infected wounds with symptoms longer than 4 weeks
- Infections from human or animal bites, prosthetic devices, bedsores, diabetic or peripheral artery disease ulcers, suspected Buruli ulcer, or infected burns
- Hospital-acquired infections including post-surgical site infections
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Masanga Hospital
Masokori, Sierra Leone
Actively Recruiting
Research Team
F
Frieder Schaumburg, MD
CONTACT
I
Ioana D Olaru, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here